Cargando…

Tirzepatide for type 2 diabetes

One in ten adults worldwide is living with diabetes, with 95% having type 2 diabetes (T2D). Sustained glycaemic control in people with T2D is difficult to achieve despite recent advances in T2D management with the advent of glucagon-like peptide 1 receptor agonists (GLP1RA) and sodium–glucose cotran...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Sarah L, Marrs, Joel C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470858/
https://www.ncbi.nlm.nih.gov/pubmed/37664792
http://dx.doi.org/10.7573/dic.2023-6-1
_version_ 1785099775745458176
author Anderson, Sarah L
Marrs, Joel C
author_facet Anderson, Sarah L
Marrs, Joel C
author_sort Anderson, Sarah L
collection PubMed
description One in ten adults worldwide is living with diabetes, with 95% having type 2 diabetes (T2D). Sustained glycaemic control in people with T2D is difficult to achieve despite recent advances in T2D management with the advent of glucagon-like peptide 1 receptor agonists (GLP1RA) and sodium–glucose cotransporter 2 inhibitors (SGLT2i). Tirzepatide represents a first-in-class agent as a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP1RA to be approved in the USA and Europe for the treatment of T2D. This narrative review intends to list and discuss the glycaemic efficacy, key safety and weight loss outcomes related to the treatment of T2D with tirzepatide. Tirzepatide has been evaluated in five published clinical trials (n=6278) within the SURPASS clinical trial programme, with a focus on glycaemic control and weight loss. These trials have demonstrated significant improvements in glycosylated haemoglobin (–1.24% to –2.11% versus placebo and –0.6% to –1.14% versus active comparator) and weight (up to 15.5 kg versus placebo or active comparator) in patients with T2D. Notably, tirzepatide exhibited superior glycaemic control and weight loss when compared directly with a GLP1RA. Adverse events with the use of tirzepatide are similar to other approved GLP1RA and are predominantly gastrointestinal (nausea, vomiting). The tirzepatide cardiovascular outcomes trial (SURPASS-CVOT) is in progress and is expected to be completed in the fall of 2024. Tirzepatide represents an attractive new option and first-in-class agent for the treatment of T2D in people unable to achieve their glycaemic or weight management goals.
format Online
Article
Text
id pubmed-10470858
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioExcel Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-104708582023-09-01 Tirzepatide for type 2 diabetes Anderson, Sarah L Marrs, Joel C Drugs Context Review One in ten adults worldwide is living with diabetes, with 95% having type 2 diabetes (T2D). Sustained glycaemic control in people with T2D is difficult to achieve despite recent advances in T2D management with the advent of glucagon-like peptide 1 receptor agonists (GLP1RA) and sodium–glucose cotransporter 2 inhibitors (SGLT2i). Tirzepatide represents a first-in-class agent as a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP1RA to be approved in the USA and Europe for the treatment of T2D. This narrative review intends to list and discuss the glycaemic efficacy, key safety and weight loss outcomes related to the treatment of T2D with tirzepatide. Tirzepatide has been evaluated in five published clinical trials (n=6278) within the SURPASS clinical trial programme, with a focus on glycaemic control and weight loss. These trials have demonstrated significant improvements in glycosylated haemoglobin (–1.24% to –2.11% versus placebo and –0.6% to –1.14% versus active comparator) and weight (up to 15.5 kg versus placebo or active comparator) in patients with T2D. Notably, tirzepatide exhibited superior glycaemic control and weight loss when compared directly with a GLP1RA. Adverse events with the use of tirzepatide are similar to other approved GLP1RA and are predominantly gastrointestinal (nausea, vomiting). The tirzepatide cardiovascular outcomes trial (SURPASS-CVOT) is in progress and is expected to be completed in the fall of 2024. Tirzepatide represents an attractive new option and first-in-class agent for the treatment of T2D in people unable to achieve their glycaemic or weight management goals. BioExcel Publishing Ltd 2023-08-22 /pmc/articles/PMC10470858/ /pubmed/37664792 http://dx.doi.org/10.7573/dic.2023-6-1 Text en Copyright © 2023 Anderson SL, Marrs JC https://creativecommons.org/licenses/by-nc-nd/4.0/Published by Drugs in Context under Creative Commons License Deed CC BY NC ND 4.0, which allows anyone to copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without permission.
spellingShingle Review
Anderson, Sarah L
Marrs, Joel C
Tirzepatide for type 2 diabetes
title Tirzepatide for type 2 diabetes
title_full Tirzepatide for type 2 diabetes
title_fullStr Tirzepatide for type 2 diabetes
title_full_unstemmed Tirzepatide for type 2 diabetes
title_short Tirzepatide for type 2 diabetes
title_sort tirzepatide for type 2 diabetes
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10470858/
https://www.ncbi.nlm.nih.gov/pubmed/37664792
http://dx.doi.org/10.7573/dic.2023-6-1
work_keys_str_mv AT andersonsarahl tirzepatidefortype2diabetes
AT marrsjoelc tirzepatidefortype2diabetes